ATT循环方案治疗复发及难治性非霍奇金恶性淋巴瘤  

Efficacy of Alternating Triple Therapy on Relapsed or Refractory Non-Hodgkin’s Lymphoma

作　　者：田红[1] 陈捷[1] 吴颖[1] 李莉莉[1] 

机构地区：[1]南京军区福州总医院血液科,福建福州350025

出　　处：《癌症》2008年第6期633-635,共3页Chinese Journal of Cancer

摘　　要：背景与目的:复发性和难治性非霍奇金恶性淋巴瘤(non-Hodgkin's lymphoma,NHL)的治疗一直是临床的难题之一。三联循环方案(alternating triple therapy,ATT)是ASHAP、m-BACOD、MINE3种方案每3周交替使用。本研究的目的是探讨ATT治疗复发及难治性NHL的疗效。方法:回顾性分析用ATT方案治疗的38例复发及难治性NHL患者的临床资料,其中复发性NHL28例,难治性NHL10例。结果:10例(26.3%)患者达到完全缓解,12例(31.6%)达到部分缓解,总有效率为63.2%。B细胞性淋巴瘤总有效率为60.0%(12/20),而T细胞性淋巴瘤总有效率为55.6%(10/18)。≤60岁年龄组总有效率为65.4%(17/26),>60岁组总有效率为41.7%(5/12)。全组中位随访时间11个月,1年总生存率42.1%(16/38),2年总生存率为13.2%(5/38)。毒副作用以骨髓抑制为主。结论:ATT循环方案对于复发及难治性NHL有较好的疗效,毒副反应患者可以耐受,值得在更多病例中进一步研究。BACKGROUND ＆ OBJECTIVE： Treatment of relapsed or refractory non-Hodgkin＇s lymphoma （NHL） remains difficult. This study was to evaluate the efficacy of alternating triple therapy （ATT）, alternating administration of ASHAP, m-BACOD, and MINE regimens every 3 weeks, on relapsed or refractory NHL. METHODS： Clinical data of 38 patients with relapsed or refractory NHL （28 relapsed NHL and 10 refractory NHL） treated with ATT were analyzed. RESULTS： Of the 38 patients, 10 （26.3%） achieved complete remission and 12 （31.6%） achieved partial remission; the overall response rate was 57.9%. The response rate was 60.0% in B-cell lymphoma patients and 55.6% in T-cell lymphoma patients; it was 65.4% in the patients of ≤60 years old and 41.7% in the patients of 〉60 years old. With a median follow-up of 11 months, the 1- and 2-year survival rates were 42.1% and 13.2%, respectively. The major adverse event was myelosuppression. CONCLUSIONS： ATT is effective and well tolerated in patients with relapsed or refractory NHL. Further clinical study is warranted.

关 键 词：非霍奇金淋巴瘤 联合化疗 疗效 

分 类 号：R733.1[医药卫生—肿瘤]